Delay in the diagnosis and treatment of tuberculosis in prisons in Mato Grosso do Sul, Brazil.


Journal

Revista da Sociedade Brasileira de Medicina Tropical
ISSN: 1678-9849
Titre abrégé: Rev Soc Bras Med Trop
Pays: Brazil
ID NLM: 7507456

Informations de publication

Date de publication:
2023
Historique:
received: 09 01 2023
accepted: 26 05 2023
medline: 27 7 2023
pubmed: 26 7 2023
entrez: 26 7 2023
Statut: epublish

Résumé

The number of tuberculosis (TB) cases in prisons is higher than that in the general population and has been reported as the most common cause of death in prisons. This study evaluated the delay in the diagnosis and treatment of TB in Brazilian prisons. A retrospective cohort study was conducted between 2007 and 2015 using data from the five largest male prisons in Mato Grosso do Sul, Brazil. TB case data was collected from the National Database of Notifiable Diseases (SINAN), GAL-LACEN, and prison medical records. The following variables were recorded: prison, year of diagnosis, age, race, education, HIV status, smoking status, comorbidities, number of symptoms, percentage of cures, delay in diagnosis, patient delay, provider delay, laboratory delay, and delay in treatment. Descriptive statistics were used for the variables of interest. A total of 362 pulmonary TB cases were identified. The average time between the first symptom and reporting of data was 94 days. The mean time between symptom onset and laboratory diagnosis was 91 days. The average time from symptom onset to first consultation was 80 days. The time between diagnosis and treatment initiation was 5 days. Delays were significant between reporting of the first symptoms and diagnosis and significantly smaller from the time between notification and start of treatment. Control strategies should be implemented to diagnose cases through active screening, to avoid delays in diagnosis and treatment, and to reduce TB transmission.

Sections du résumé

BACKGROUND BACKGROUND
The number of tuberculosis (TB) cases in prisons is higher than that in the general population and has been reported as the most common cause of death in prisons. This study evaluated the delay in the diagnosis and treatment of TB in Brazilian prisons.
METHODS METHODS
A retrospective cohort study was conducted between 2007 and 2015 using data from the five largest male prisons in Mato Grosso do Sul, Brazil. TB case data was collected from the National Database of Notifiable Diseases (SINAN), GAL-LACEN, and prison medical records. The following variables were recorded: prison, year of diagnosis, age, race, education, HIV status, smoking status, comorbidities, number of symptoms, percentage of cures, delay in diagnosis, patient delay, provider delay, laboratory delay, and delay in treatment. Descriptive statistics were used for the variables of interest.
RESULTS RESULTS
A total of 362 pulmonary TB cases were identified. The average time between the first symptom and reporting of data was 94 days. The mean time between symptom onset and laboratory diagnosis was 91 days. The average time from symptom onset to first consultation was 80 days. The time between diagnosis and treatment initiation was 5 days.
CONCLUSIONS CONCLUSIONS
Delays were significant between reporting of the first symptoms and diagnosis and significantly smaller from the time between notification and start of treatment. Control strategies should be implemented to diagnose cases through active screening, to avoid delays in diagnosis and treatment, and to reduce TB transmission.

Identifiants

pubmed: 37493729
pii: S0037-86822023000100322
doi: 10.1590/0037-8682-0015-2023
pmc: PMC10367220
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e00152023

Références

J Bras Pneumol. 2011 Jul-Aug;37(4):512-20
pubmed: 21881742
Rev Panam Salud Publica. 2019 Jan 04;43:e16
pubmed: 31093240
BMC Public Health. 2004 May 29;4:18
pubmed: 15169548
BMC Public Health. 2002 Sep 25;2:23
pubmed: 12296975
Health Policy Plan. 2007 Sep;22(5):329-34
pubmed: 17698889
BMC Infect Dis. 2015 Jan 22;15:24
pubmed: 25608746
Eur Respir J. 2008 Nov;32(5):1415-6
pubmed: 18978146
BMC Infect Dis. 2016 Oct 3;16(1):533
pubmed: 27716170
BMC Pulm Med. 2018 May 2;18(1):64
pubmed: 29716569
PLoS Med. 2010 Dec 21;7(12):e1000381
pubmed: 21203587
Cien Saude Colet. 2016 Jun;21(7):2147-60
pubmed: 27383348
BMC Infect Dis. 2009 Jun 11;9:91
pubmed: 19519917
PLoS Med. 2019 Jan 24;16(1):e1002737
pubmed: 30677013
Emerg Infect Dis. 2015 Mar;21(3):452-5
pubmed: 25642998

Auteurs

Carla Celina Ribeiro (CC)

Universidade Federal da Grande Dourados, Faculdade de Ciências da Saúde, Dourados, MS, Brasil.

Andrea da Silva Santos (ADS)

Universidade Federal da Grande Dourados, Faculdade de Ciências da Saúde, Dourados, MS, Brasil.

Daniel Henrique Tshua (DH)

Secretaria Estadual de Saúde de Mato Grosso do Sul, Campo Grande, MS, Brasil.

Roberto Dias de Oliveira (RD)

Universidade Federal da Grande Dourados, Faculdade de Ciências da Saúde, Dourados, MS, Brasil.
Universidade Estadual de Mato Grosso do Sul, Curso de Enfermagem, Dourados, MS, Brasil.

Everton Ferreira Lemos (EF)

Universidade Estadual de Mato Grosso do Sul, Faculdade de Medicina, Campo Grande, MS, Brasil.

Paul Bourdillon (P)

Yale University School of Public Health, Department of Epidemiology of Microbial Diseases, New Haven, United States of America.

Alexandre Laranjeira (A)

Faculdade de Medicina de São José do Rio Preto, Hospital de Base, São José do Rio Preto, SP, Brasil.

Crhistinne Cavalheiro Maymone Gonçalves (CCM)

Secretaria Estadual de Saúde de Mato Grosso do Sul, Campo Grande, MS, Brasil.
Universidade Estadual de Mato Grosso do Sul, Curso de Medicina, Campo Grande, MS, Brasil.

Jason Andrews (J)

Stanford University School of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford, CA, United States of America.

Albert Ko (A)

Yale University School of Public Health, Department of Epidemiology of Microbial Diseases, New Haven, United States of America.

Julio Croda (J)

Universidade Estadual de Mato Grosso do Sul, Curso de Medicina, Campo Grande, MS, Brasil.
Fundação Oswaldo Cruz, Mato Grosso do Sul, Campo Grande, MS, Brasil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH